Effects of a Ketogenic Diet on Auditory Gating in DBA/2 Mice: A Proof-of-concept Study

Overview

Journal Schizophr Res

Specialty Psychiatry

Date 2015 Oct 11

PMID 26453015

Citations 4

Authors

Jason R Tregellas

Jason Smucny

Kristina T Legget

Karen E Stevens

Affiliations

Soon will be listed here.

Abstract

Although the ketogenic diet has shown promise in a pilot study and case report in schizophrenia, its effects in animal models of hypothesized disease mechanisms are unknown. This study examined effects of treatment with the ketogenic diet on hippocampal P20/N40 gating in DBA/2 mice, a translational endophenotype that mirrors inhibitory deficits in P50 sensory gating in schizophrenia patients. As expected, the diet increased blood ketone levels. Animals with the highest ketone levels showed the lowest P20/N40 gating ratios. These preliminary results suggest that the ketogenic diet may effectively target sensory gating deficits and is a promising area for additional research in schizophrenia.

Citing Articles

The Potential Role of the Ketogenic Diet in Serious Mental Illness: Current Evidence, Safety, and Practical Advice.

Rog J, Wingralek Z, Nowak K, Grudzien M, Grunwald A, Banaszek A J Clin Med. 2024; 13(10).

PMID: 38792361 PMC: 11122005. DOI: 10.3390/jcm13102819.

Gut Microbiota and Neuroplasticity.

Murciano-Brea J, Garcia-Montes M, Geuna S, Herrera-Rincon C Cells. 2021; 10(8).

PMID: 34440854 PMC: 8392499. DOI: 10.3390/cells10082084.

Ketogenic Therapy in Serious Mental Illness: Emerging Evidence.

Sarnyai Z, Palmer C Int J Neuropsychopharmacol. 2020; 23(7):434-439.

PMID: 32573722 PMC: 7387764. DOI: 10.1093/ijnp/pyaa036.

Modified Mediterranean Diet for Enrichment of Short Chain Fatty Acids: Potential Adjunctive Therapeutic to Target Immune and Metabolic Dysfunction in Schizophrenia?.

Joseph J, Depp C, Shih P, Cadenhead K, Schmid-Schonbein G Front Neurosci. 2017; 11:155.

PMID: 28396623 PMC: 5366345. DOI: 10.3389/fnins.2017.00155.

References

Grunwald T, Boutros N, Pezer N, von Oertzen J, Fernandez G, Schaller C . Neuronal substrates of sensory gating within the human brain. Biol Psychiatry. 2003; 53(6):511-9. DOI: 10.1016/s0006-3223(02)01673-6. View

MCGHIE A, Chapman J . Disorders of attention and perception in early schizophrenia. Br J Med Psychol. 1961; 34:103-16. DOI: 10.1111/j.2044-8341.1961.tb00936.x. View

Pacheco A, EASTERLING W, PRYER M . A PILOT STUDY OF THE KETOGENIC DIET IN SCHIZOPHRENIA. Am J Psychiatry. 1965; 121:1110-1. DOI: 10.1176/ajp.121.11.1110. View

Venables P . INPUT DYSFUNCTION IN SCHIZOPHRENIA. Prog Exp Pers Res. 1964; 72:1-47. View

Liddle P, Friston K, Frith C, Hirsch S, Jones T, Frackowiak R . Patterns of cerebral blood flow in schizophrenia. Br J Psychiatry. 1992; 160:179-86. DOI: 10.1192/bjp.160.2.179. View

Molina V, Sanz J, Sarramea F, Benito C, Palomo T . Prefrontal atrophy in first episodes of schizophrenia associated with limbic metabolic hyperactivity. J Psychiatr Res. 2004; 39(2):117-27. DOI: 10.1016/j.jpsychires.2004.06.008. View

Friston K, Liddle P, Frith C, Hirsch S, Frackowiak R . The left medial temporal region and schizophrenia. A PET study. Brain. 1992; 115 ( Pt 2):367-82. DOI: 10.1093/brain/115.2.367. View

Hashimoto K, Iyo M, Freedman R, Stevens K . Tropisetron improves deficient inhibitory auditory processing in DBA/2 mice: role of alpha 7 nicotinic acetylcholine receptors. Psychopharmacology (Berl). 2005; 183(1):13-9. DOI: 10.1007/s00213-005-0142-0. View

Olincy A, Harris J, Johnson L, Pender V, Kongs S, Allensworth D . Proof-of-concept trial of an alpha7 nicotinic agonist in schizophrenia. Arch Gen Psychiatry. 2006; 63(6):630-8. DOI: 10.1001/archpsyc.63.6.630. View

10.

Olincy A, Stevens K . Treating schizophrenia symptoms with an alpha7 nicotinic agonist, from mice to men. Biochem Pharmacol. 2007; 74(8):1192-201. PMC: 2134979. DOI: 10.1016/j.bcp.2007.07.015. View

11.

Stevens K, Adams C, Mellott T, Robbins E, Kisley M . Perinatal choline deficiency produces abnormal sensory inhibition in Sprague-Dawley rats. Brain Res. 2008; 1237:84-90. PMC: 2586157. DOI: 10.1016/j.brainres.2008.08.047. View

12.

Kraft B, Westman E . Schizophrenia, gluten, and low-carbohydrate, ketogenic diets: a case report and review of the literature. Nutr Metab (Lond). 2009; 6:10. PMC: 2652467. DOI: 10.1186/1743-7075-6-10. View

13.

Singer P, Feldon J, Yee B . Are DBA/2 mice associated with schizophrenia-like endophenotypes? A behavioural contrast with C57BL/6 mice. Psychopharmacology (Berl). 2009; 206(4):677-98. DOI: 10.1007/s00213-009-1568-6. View

14.

Schobel S, Lewandowski N, Corcoran C, Moore H, Brown T, Malaspina D . Differential targeting of the CA1 subfield of the hippocampal formation by schizophrenia and related psychotic disorders. Arch Gen Psychiatry. 2009; 66(9):938-46. PMC: 2797730. DOI: 10.1001/archgenpsychiatry.2009.115. View

15.

Williams T, Nuechterlein K, Subotnik K, Yee C . Distinct neural generators of sensory gating in schizophrenia. Psychophysiology. 2010; 48(4):470-8. PMC: 2994969. DOI: 10.1111/j.1469-8986.2010.01119.x. View

16.

Tamminga C, Stan A, Wagner A . The hippocampal formation in schizophrenia. Am J Psychiatry. 2010; 167(10):1178-93. DOI: 10.1176/appi.ajp.2010.09081187. View

17.

Miwa J, Freedman R, Lester H . Neural systems governed by nicotinic acetylcholine receptors: emerging hypotheses. Neuron. 2011; 70(1):20-33. PMC: 4418790. DOI: 10.1016/j.neuron.2011.03.014. View

18.

Wildeboer-Andrud K, Stevens K . The smoking cessation drug varenicline improves deficient P20-N40 inhibition in DBA/2 mice. Pharmacol Biochem Behav. 2011; 100(1):17-24. PMC: 3183147. DOI: 10.1016/j.pbb.2011.07.001. View

19.

Tamminga C, Southcott S, Sacco C, Wagner A, Ghose S . Glutamate dysfunction in hippocampus: relevance of dentate gyrus and CA3 signaling. Schizophr Bull. 2012; 38(5):927-35. PMC: 3446225. DOI: 10.1093/schbul/sbs062. View

20.

Winterer G, Gallinat J, Brinkmeyer J, Musso F, Kornhuber J, Thuerauf N . Allosteric alpha-7 nicotinic receptor modulation and P50 sensory gating in schizophrenia: a proof-of-mechanism study. Neuropharmacology. 2012; 64:197-204. DOI: 10.1016/j.neuropharm.2012.06.040. View